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METHODS
• The Psoriasis Symptom Inventory (PSI) is a psoriasis-specific, 8-item patient-reported outcome (PRO) instrument measuring the severity of psoriasis signs and symptoms [1] [2] [3] [4] -Measures severity in 8 items: itch, redness, scaling, burning, stinging, cracking, flaking, pain -Each item is scored from 0 (not at all severe) to 4 (very severe) for a total score ranging from 0 (best) to 32 (worst) -A total PSI score of 0 indicates no psoriasis signs or symptoms -PSI response is defined as total score ≤ 8, with each sign or symptom rated as either 0 (not at all) or 1 (mild) -Two recall versions of PSI: 24-hr (for use in clinical trials as a daily diary) and 7-day recall (for use in clinical practice) • The PSI was developed in accordance with the US Food and Drug Administration's PRO Guidelines 5
• Content validity of the PSI is supported by qualitative research based on concept elicitation focus groups, concept elicitation individual interviews, and cognitive interviews 1
• The PSI has demonstrated good psychometric properties in a stand-alone quantitative study and a secondary analysis of data from a phase 2 study of brodalumab in patients with moderate to severe plaque psoriasis [2] [3] • The PSI can detect meaningful changes in psoriasis severity based on improvements in Psoriasis Area and Severity Index (PASI) and static Physician Global Assessment (sPGA) 6 • Equivalency has been shown between the paper and electronic versions of the PSI 4
• The PSI was implemented as an electronic daily diary in the brodalumab phase 3 psoriasis program; an understanding of the measurement properties of the PSI administered as a daily diary in a clinical trial program is needed
• This was a prespecified, secondary analysis of pooled data from a phase 3 study of brodalumab in patients with moderate to severe plaque psoriasis (NCT01708590) • Outcome measures from the phase 3 study that were used in this psychometric analysis included -PASI: Measure of plaque qualities, including induration, erythema, and desquamation, and the area involved with psoriasis, with scores ranging from 0 (no disease) to 72 (maximal disease) -sPGA: Measure of the degree of psoriasis severity at a single point in time on a 6-point scale from 0 (no psoriasis) to 5 (very severe psoriasis) -Psoriasis-affected body surface area (BSA): Measure of the percentage of a patient's body surface that is involved with psoriasis -PSI: Measure of the severity of psoriasis signs and symptoms -Dermatology Life Quality Index (DLQI): Measure of the effect of skin disease on health-related quality of life (HRQoL), with scores ranging from 0 (no effect at all) to 30 (extremely large effect) -Medical Outcomes Short Form 36-item Health Survey Version 2 (SF-36): A generic HRQoL instrument that measures physical and mental health status • Psychometric evaluations -Confirmatory factor analysis (CFA) and Rasch analysis to determine dimensionality and item performance -Cronbach's α to determine internal consistency reliability -Intraclass correlation coefficients (ICCs) among patients with stable disease to determine test-retest reliability -Pearson's correlation coefficients to determine convergent and discriminant validity -Analysis of variance (ANOVA) to compare PSI weekly average scores among groups of patients with different levels of improvement based on PASI (PASI < 50, PASI 50 to < 75, and PASI ≥ 75) and sPGA (sPGA 0/1 and sPGA ≥ 2) to examine the ability of the PSI to detect change; post-hoc comparisons were used to test for differences between the levels of each grouping variable -Cohen's Kappa (κ) to assess the level of agreement between PSI responders and standard measures of clinical response, ie, PASI-PASI 75 and PASI 90-and sPGA-sPGA 0/1 and sPGA improvement ≥ 2 from baseline 
